Brought to you by 
Currax gains NA license to OptiNose's Onzetra Xsail migraine treatment
02 Oct 2019
Executive Summary
Currax Pharmaceuticals LLC (formerly Pernix Therapeutics) gained exclusive US, Canadian, and Mexican marketing rights to OptiNose Inc.'s Onzetra Xsail (sumatriptan) dry powder formulation acute migraine treatment.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Currax gains NA license to OptiNose's Onzetra Xsail migraine treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice